Oncolytics Biotech Inc.
ONCY
$0.5919
$0.02193.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.91% | -41.69% | -4.58% | -6.33% | 14.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.34% | -11.89% | 8.59% | 30.00% | 3.77% |
| Operating Income | 7.34% | 11.89% | -8.59% | -30.00% | -3.77% |
| Income Before Tax | -98.91% | 5.49% | 4.92% | -7.44% | 54.14% |
| Income Tax Expenses | -48.10% | 69.23% | 98.29% | -- | -24.76% |
| Earnings from Continuing Operations | -97.31% | 5.44% | 4.27% | -7.44% | 53.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.31% | 5.44% | 4.27% | -7.44% | 53.94% |
| EBIT | 7.34% | 11.89% | -8.59% | -30.00% | -3.77% |
| EBITDA | 7.25% | 12.05% | -8.53% | -29.99% | -3.81% |
| EPS Basic | -87.79% | 14.34% | 18.86% | 10.88% | 62.89% |
| Normalized Basic EPS | -89.30% | 14.35% | 19.48% | 10.90% | 63.01% |
| EPS Diluted | -87.79% | 14.34% | 18.86% | 10.88% | 62.89% |
| Normalized Diluted EPS | -89.30% | 14.35% | 19.48% | 10.90% | 63.01% |
| Average Basic Shares Outstanding | 5.11% | 10.33% | 18.03% | 20.69% | 23.97% |
| Average Diluted Shares Outstanding | 5.11% | 10.33% | 18.03% | 20.69% | 23.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |